2024-11-14 - Analysis Report
## Intuitive Surgical Inc (ISRG) Stock Analysis Report 

**Company Overview:** Intuitive Surgical Inc. is a medical device company that develops, manufactures, and markets robotic-assisted surgical systems.

**1. Performance Analysis:**

* **Cumulative Returns:** ISRG has delivered a cumulative return of 388.01%, significantly outperforming the S&P 500 (VOO) with a return of 179.47%.
* **Relative Performance:**  The current relative performance of ISRG vs. VOO is 208.54%, which puts it in the 78th percentile of its historical range.
* **Alpha and Beta:** ISRG consistently demonstrates strong alpha (above-average returns compared to the market) and a beta slightly above 1, indicating higher volatility than the market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|
| 2015-2017  | 108.3% | 16.7% | 69.9% | 0.8 | 43.3 |
| 2016-2018  | 162.5% | 23.9% | 130.2% | 1.2 | 56.9 |
| 2017-2019  | 176.3% | 23.9% | 124.6% | 1.4 | 70.2 |
| 2018-2020  | 118.0% | 40.4% | 70.7% | 1.2 | 97.1 |
| 2019-2021  | 131.3% | 40.4% | 31.3% | 1.2 | 128.0 |
| 2020-2022  | 33.3% | 45.8% | 9.7% | 1.2 | 94.5 |
| 2021-2023  | 26.5% | 45.8% | -8.4% | 1.4 | 120.2 |
| 2022-2024  | 49.1% | 45.1% | 18.6% | 1.3 | 191.3 |


**2. Recent Price Movement:**

* **Closing Price:** $536.69 (Last-market: $536.73)
* **5-Day Moving Average:** $534.05
* **20-Day Moving Average:** $516.31
* **60-Day Moving Average:** $495.01

**3. Technical Indicators:**

* **RSI:** 73.35, indicating the stock is in overbought territory.
* **PPO:** 0.39, suggesting potential strength.
* **Delta_Previous_Relative_Divergence:** +13.87, signaling short-term bullish momentum.
* **Expected Return:** 10.43%, indicating an estimated long-term (2+ years) outperformance compared to the S&P 500. 

**4. Recent Earnings & Outlook:**

| Date        | EPS     | Revenue |
|-------------|---------|---------|
| 2024-10-18  | 1.59    | 2.04 B$ |
| 2024-07-19  | 1.48    | 2.01 B$ |
| 2024-04-19  | 1.54    | 1.89 B$ |
| 2023-10-20  | 1.18    | 1.74 B$ |
| 2024-10-18  | 1.18    | 1.74 B$ |

* **Recent Earnings (2024-10-18):**  EPS of 1.59 exceeded analysts' estimates of 1.48, indicating strong performance. Revenue also came in above expectations.
* **Outlook:**  Analysts remain optimistic about ISRG's future growth potential, citing strong demand for robotic-assisted surgical procedures and continued innovation in the company's product line.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter       | Revenue  | Profit Margin |
|-------------|----------|--------------|
| 2024-09-30  | $2.04B  | 67.41%       |
| 2024-06-30  | $2.01B  | 68.30%       |
| 2024-03-31  | $1.89B  | 65.87%       |
| 2023-12-31  | $1.93B  | 66.24%       |
| 2023-09-30  | $1.74B  | 66.94%       |

**2) Capital and Profitability:**

| Quarter       | Equity   | ROE |
|-------------|----------|-----|
| 2024-09-30  | $15.58B | 3.63% |
| 2024-06-30  | $14.71B | 3.58% |
| 2024-03-31  | $13.96B | 3.90% |
| 2023-12-31  | $13.31B | 4.56% |
| 2023-09-30  | $12.54B | 3.32% |

* **Revenue and Profitability:**  ISRG consistently demonstrates strong revenue growth and profitability, maintaining high profit margins.
* **Capital and Profitability:**  The company boasts a strong capital base and a reasonable return on equity.

**6. News and Recent Issues:**

* **Recent Earnings Release:**  ISRG recently reported its Q3 2024 earnings, exceeding expectations and showcasing strong growth.
* **Market Outlook:** Analysts are generally optimistic about ISRG's future prospects. They cite the company's dominance in the robotic-assisted surgical market, continuous product development, and the increasing adoption of minimally invasive procedures as key drivers for growth.
* **Analyst Opinions:**  Most analysts rate ISRG as a "buy" or "strong buy", reflecting their positive outlook on the company's long-term growth potential.
* **Performance Highlights:** ISRG has been recognized for its strong financial performance and market leadership. It has consistently outperformed the broader market and earned recognition as a top-performing company in the medical device sector.

**7. Summary:**

ISRG is a leading player in the robotic-assisted surgical market with a strong track record of growth and profitability. Its recent earnings report further reinforces the positive outlook for the company. While the stock is currently in overbought territory, the long-term growth potential remains compelling, supported by a robust financial position and continued innovation. Analysts remain optimistic, suggesting the stock remains a good buy for investors seeking long-term exposure to the healthcare sector.

**Note:**  This report is based on publicly available information and should not be considered financial advice. Always consult with a qualified financial advisor before making any investment decisions. 
